Hyesun Park1, Hiroto Hatabu2, Biagio Ricciuti3, Safiya J Aijazi3, Mark M Awad3, Mizuki Nishino4. 1. Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA; Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. 2. Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. 3. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. 4. Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA; Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. Electronic address: mizuki_nishino@dfci.harvard.edu.
Abstract
PURPOSE: Investigate the incidence and imaging characteristics of radiologically-evident immune-related adverse events (irAEs) on body CT in patients with small-cell lung cancer (SCLC) treated with immune-checkpoint inhibitors. METHODS: The study included 53 patients with relapsed/refractory SCLC (27 men, 26 women) treated with PD-1/PD-L1 inhibitors alone or in combination with CTLA-4 inhibition, who had baseline and at least one follow-up body CT during therapy. Body CT scans were reviewed to detect and characterize organ-specific irAEs including thyroiditis, pneumonitis, hepatitis, pancreatitis, enteritis, and colitis. RESULTS: Nineteen patients (36 %) developed radiologically-evident irAEs. The median time from therapy initiation to irAE onset was 7.1 weeks. Pneumonitis and colitis were most common, noted in 9 patients (17 %) each. Seven colitis cases demonstrated pancolitis, and two cases showed segmental colitis associated with diverticulosis. The common radiographic patterns of pneumonitis were acute interstitial pneumonia (AIP)/acute respiratory distress syndrome (ARDS) pattern (n = 4) and cryptogenic organizing pneumonia (COP) pattern (n = 3). Other irAEs included thyroiditis (n = 3), enteritis (n = 2), hepatitis (n = 1), and pancreatitis (n = 1). Older age (p = 0.03) and prior radiotherapy to any organ (p = 0.03) was associated with overall irAEs. Prior chest radiotherapy was significantly associated with pneumonitis or thyroiditis (p = 0.0004). CONCLUSION: Radiologically-evident irAEs were noted on body CT in 36 % of patients with SCLC treated with immune-checkpoint inhibitors. Colitis and pneumonitis were most common. Prior chest radiotherapy was a predictor of the development of both pneumonitis and thyroiditis. Awareness of risk factors and CT findings of irAEs is important for early detection and accurate diagnosis of potentially serious immunotherapy toxicities.
PURPOSE: Investigate the incidence and imaging characteristics of radiologically-evident immune-related adverse events (irAEs) on body CT in patients with small-cell lung cancer (SCLC) treated with immune-checkpoint inhibitors. METHODS: The study included 53 patients with relapsed/refractory SCLC (27 men, 26 women) treated with PD-1/PD-L1 inhibitors alone or in combination with CTLA-4 inhibition, who had baseline and at least one follow-up body CT during therapy. Body CT scans were reviewed to detect and characterize organ-specific irAEs including thyroiditis, pneumonitis, hepatitis, pancreatitis, enteritis, and colitis. RESULTS: Nineteen patients (36 %) developed radiologically-evident irAEs. The median time from therapy initiation to irAE onset was 7.1 weeks. Pneumonitis and colitis were most common, noted in 9 patients (17 %) each. Seven colitis cases demonstrated pancolitis, and two cases showed segmental colitis associated with diverticulosis. The common radiographic patterns of pneumonitis were acute interstitial pneumonia (AIP)/acute respiratory distress syndrome (ARDS) pattern (n = 4) and cryptogenic organizing pneumonia (COP) pattern (n = 3). Other irAEs included thyroiditis (n = 3), enteritis (n = 2), hepatitis (n = 1), and pancreatitis (n = 1). Older age (p = 0.03) and prior radiotherapy to any organ (p = 0.03) was associated with overall irAEs. Prior chest radiotherapy was significantly associated with pneumonitis or thyroiditis (p = 0.0004). CONCLUSION: Radiologically-evident irAEs were noted on body CT in 36 % of patients with SCLC treated with immune-checkpoint inhibitors. Colitis and pneumonitis were most common. Prior chest radiotherapy was a predictor of the development of both pneumonitis and thyroiditis. Awareness of risk factors and CT findings of irAEs is important for early detection and accurate diagnosis of potentially serious immunotherapy toxicities.
Authors: Karthik Suresh; Kevin J Psoter; Khinh Ranh Voong; Bairavi Shankar; Patrick M Forde; David S Ettinger; Kristen A Marrone; Ronan J Kelly; Christine L Hann; Benjamin Levy; Josephine L Feliciano; Julie R Brahmer; David Feller-Kopman; Andrew D Lerner; Hans Lee; Lonny Yarmus; Russell K Hales; Franco D'Alessio; Sonye K Danoff; Jarushka Naidoo Journal: J Thorac Oncol Date: 2018-11-30 Impact factor: 15.609
Authors: Mizuki Nishino; Nikhil H Ramaiya; Mark M Awad; Lynette M Sholl; Jennifer A Maattala; Myriam Taibi; Hiroto Hatabu; Patrick A Ott; Philippe F Armand; F Stephen Hodi Journal: Clin Cancer Res Date: 2016-08-17 Impact factor: 12.531
Authors: Jarushka Naidoo; Xuan Wang; Kaitlin M Woo; Tunc Iyriboz; Darragh Halpenny; Jane Cunningham; Jamie E Chaft; Neil H Segal; Margaret K Callahan; Alexander M Lesokhin; Jonathan Rosenberg; Martin H Voss; Charles M Rudin; Hira Rizvi; Xue Hou; Katherine Rodriguez; Melanie Albano; Ruth-Ann Gordon; Charles Leduc; Natasha Rekhtman; Bianca Harris; Alexander M Menzies; Alexander D Guminski; Matteo S Carlino; Benjamin Y Kong; Jedd D Wolchok; Michael A Postow; Georgina V Long; Matthew D Hellmann Journal: J Clin Oncol Date: 2016-09-30 Impact factor: 44.544
Authors: Kyung Won Kim; Nikhil H Ramaiya; Katherine M Krajewski; Jyothi P Jagannathan; Sree Harsha Tirumani; Amitabh Srivastava; Nageatte Ibrahim Journal: Invest New Drugs Date: 2013-02-14 Impact factor: 3.850
Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: M Catherine Pietanza; Saiama N Waqar; Lee M Krug; Afshin Dowlati; Christine L Hann; Alberto Chiappori; Taofeek K Owonikoko; Kaitlin M Woo; Robert J Cardnell; Junya Fujimoto; Lihong Long; Lixia Diao; Jing Wang; Yevgeniva Bensman; Brenda Hurtado; Patricia de Groot; Erik P Sulman; Ignacio I Wistuba; Alice Chen; Martin Fleisher; John V Heymach; Mark G Kris; Charles M Rudin; Lauren Averett Byers Journal: J Clin Oncol Date: 2018-06-15 Impact factor: 44.544